U.S. stocks opened lower as rising Treasury yields weighed on risk appetite, while oil-related names gained on persistent Middle East tensions. In premarket trading, the VanEck Semiconductor exchange-traded fund dropped more than 1%, with major chipmakers including Nvidia, AMD and Micron also down more than 1% each. Meanwhile, energy shares climbed alongside oil prices; the State Street Energy Select Sector SPDR ETF rose more than 1%, helped by gains across EOG Resources, Diamondback Energy and Targa Resources, each up more than 1%.
Key takeaways
- Semiconductors fell as higher Treasury yields pressured broader market sentiment.
- Energy stocks rose with oil prices supported by ongoing geopolitical tensions in the Middle East.
- Robinhood surged after a Morgan Stanley upgrade to overweight, signaling improved platform economics.
- Novartis jumped on positive multiple sclerosis trial data for remibrutinib, lifting expectations for the drug’s clinical progress.
- Duolingo rallied after Evercore ISI upgraded the stock, citing strong survey data.
What drove the move
Rates were the dominant early catalyst for the equity open. As Treasury yields moved higher, investors appeared to rotate away from the most rate-sensitive areas of the market, pressuring semiconductors at the start of the month. The sharp pullback in the semiconductor ETF suggested investors were repricing near-term discount-rate assumptions rather than reacting to company-specific fundamentals.
In contrast, energy stocks gained momentum because oil prices firmed. Pre-market gains in the sector were linked to ongoing tensions in the Middle East, a backdrop that can support crude through supply-risk concerns. That helped lift broad energy exposure, including individual producers and transporters that were trading up more than 1% each.
Company-specific momentum: finance, healthcare and software
Robinhood Markets rose more than 2% after Morgan Stanley upgraded the stock from equal weight to overweight. The bank said the firm’s “expanding platform is turning product velocity into stronger customer economics,” framing the move as an improvement in how rapidly the platform converts activity into durable value for customers. For investors, the upgrade added a valuation and expectations reset, particularly as the stock had been moving in step with broader market sentiment early in the session.
Novartis gained 4% following positive trial data for remibrutinib, a multiple sclerosis treatment candidate. According to the company, remibrutinib “significantly” reduced relapse rates in MS patients relative to another treatment. The market reaction suggests investors viewed the results as a meaningful step in validating clinical effectiveness—an outcome that typically strengthens confidence around probability-of-success for future regulatory and commercial milestones.
Duolingo jumped 6% after Evercore ISI upgraded the stock to outperform from in line. Evercore cited strong survey data for the company, using customer and engagement indicators as a basis for raising its stance. For the language-learning app, the upside move signals that investors were receptive to evidence that the user base and product engagement can translate into improved operating performance.
Market reaction and what investors are watching
The early pattern across sectors pointed to a classic rates versus commodities split. Semiconductors were hit as yields rose, while energy benefited as oil held up. That dynamic matters for investors because it can influence index performance even before corporate news begins to drive earnings-cycle narratives.
Going forward, investors are likely to monitor two areas closely: first, whether Treasury yields continue to trend higher, which could keep pressure on growth-tilted segments like semiconductors; and second, whether geopolitical developments sustain oil’s support. In the near term, attention will also likely shift back to company updates, including additional clinical developments and guidance signals that could change expectations for healthcare and software names.
What analysts may take from the upgrades and trial readouts
Analyst actions in the premarket moves appeared to center on improving fundamental outlooks rather than immediate earnings beats. Morgan Stanley’s upgrade of Robinhood highlighted the link between platform expansion and customer economics, while Evercore’s Duolingo upgrade emphasized survey-based strength that can underpin demand and retention assumptions. In healthcare, Novartis’ trial results provided a concrete efficacy datapoint, a type of catalyst that investors generally weigh heavily when recalibrating timelines for regulatory progress.
Next, markets will be watching for confirmation from broader trading as yields either stabilize or extend higher, and as crude prices react to any new Middle East headlines. Investors should also look ahead to scheduled economic releases and central bank communications, which can further influence rate expectations—and, by extension, sectors such as semiconductors that are sensitive to discount-rate shifts.
